InterMune, Inc.

Published Date: 14/06/2011
Category: Therapies & Markets

Research Report Decription

InterMune, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

• Detailed information on InterMune, Inc. required for business and competitor intelligence needs
• A study of the major internal and external factors affecting InterMune, Inc. in the form of a SWOT analysis
• An in-depth view of the business model of InterMune, Inc. including a breakdown and examination of key business segments
• Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for InterMune, Inc.
• Intelligence on InterMune, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about InterMune, Inc., such as business expansion, restructuring, and contract wins
• Large number of easyto-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the InterMune, Inc. and the factors that influence its strategies 
• Track strategic initiatives of the company and latest corporate news and actions 
• Assess InterMune, Inc. as a prospective partner, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on InterMune, Inc.’s business structure, strategy and prospects

Companies Mentioned:

InterMune, Inc

Paper Highlights:

InterMune is a biotech company focused on developing and commercializing therapies in pulmonology and hepatology. The company currently markets Actimmune (interferon gamma-1b) for the treatment of severe, malignant osteopetrosis and chronic granulomatous disease. It primarily operates in the US. The company is headquartered in Brisbane, California and employs 121 people. The company recorded revenues of $48.7 million during the financial year (FY) ended December 2009, an increase of 1% over FY2008. The operating loss of the company was $100.8 million during FY2009, as compared to the operating loss of $95.7million in FY2008. The net loss of the company was $116 million in FY2009, as compared to the net loss of $106.5 million in FY2008.